Global Cancer Diagnostics Market to surpass $ 170 Bn by 2025

January 27, 2020


According to recent study titled ‘Cancer Diagnostics Market Size By Application (Tumor Biomarkers Tests, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization), By Cancer Type (Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver- Lung Cancer, Melanoma, Non- Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer), By End-Use (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes) Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Russia, Japan, China, Australia, Mexico, Brazil, Argentina, South Africa, UAE, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share and Forecast, 2019-2025’, available with Market Study Report LLC, the global cancer diagnostics market will reach USD 170 billion in value by 2025.
 

Growing demand for safe, reliable, cost-effective and innovative medical products to tackle growing incidences of various cancers is propelling the growth of cancer diagnostics market share across the globe. Rise in healthcare spending among people due to increased disposable income coupled with growing establishment of diagnostics centers and research laboratories are major factors supplementing the market dynamics.
 

Initiatives are being undertaken by the government, NGOs and certain private entities to educate people regarding increasing cases of cancer and benefits of early cancer detection worldwide. As per WHO, cancer is the second leading cause of deaths in the world and in 2018, was accountable for nearly 9.6 million fatalities globally. Major causes of the disease include consumption of alcohol, tobacco, unhealthy lifestyle and physical inactivity.
 

Changing times and technological developments in healthcare sector focusing on providing real-time, accurate and fast diagnosis will support the demand for cancer diagnostic kits. Liquid biopsy along with other minimally invasive cancer diagnosis techniques will amplify industry penetration. Public and private bodies are significantly investing towards R&D in cancer diagnostics.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/859978/
 

High rate of affordability primarily in developed nations like the U.S., U.K, and Canada with easy availability of healthcare insurance facilities and cashless payment modes is steering the demand for superior cancer diagnostic tools among people. Key industry players are collaborating with research institutes to boost their R&D capacities and introduce new diagnostic products.
 

Global cancer diagnostics market share is fairly consolidated with industry players such as Abbott Laboratories, Dickinson and Company, GE Healthcare, Cancer Genetics, Sysmex Corporation, and Roche, among various others.


Frequently Asked Questions (FAQ) :

Increasing incidences of cancer among people across all age groups coupled with adequate awareness regarding the need for early diagnosis is amplifying cancer diagnostics market outlook, worldwide. Improved ability to spend on healthcare especially in developing regions such as Latin America and APAC will bolster industry penetration over the years.
In-situ hybridization market is projected to grow at a CAGR of 10.5% over 2019-2025. The technique is widely being used to determine extra copies of HER2 gene during the screening for breast cancer. Initiatives are being taken by government globally to inform women about increasing cases of breast cancer along with the implementation of fluorescent in situ hybridization.
Reports estimate that Germany cancer diagnostics market is likely to showcase a notable CAGR of 9% through 2025. The use of technologically advanced medical devices in the region along with the presence of high geriatric population prone to various types of cancer will add impetus to Germany cancer diagnostics industry forecast.
Rising occurrence of colorectal cancer in young adults is propelling the requirement for colon and rectal cancer diagnostics tools. American Cancer Society states that total number of colorectal cancer cases recorded in people under the age of 50 has risen by close to 51% since 1994 and more than 16,000 people younger than 50 years are diagnosed with colorectal cancer every year.